[1]吴文军 谢玲 李婷婷 丁任重 胡义杰.经导管主动脉瓣置换术围手术期脑卒中和脑保护研究进展[J].心血管病学进展,2024,(4):295.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.002]
 WU Wenjun,XIE Ling,LI Tingting,et al.Perioperative Transcatheter Aortic Valve Replacement for Stroke and Cerebral Protection[J].Advances in Cardiovascular Diseases,2024,(4):295.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.002]
点击复制

经导管主动脉瓣置换术围手术期脑卒中和脑保护研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年4期
页码:
295
栏目:
综述
出版日期:
2024-04-25

文章信息/Info

Title:
Perioperative Transcatheter Aortic Valve Replacement for Stroke and Cerebral Protection
作者:
吴文军 谢玲 李婷婷 丁任重 胡义杰
(陆军军医大学大坪医院心脏血管外科 重庆 400042)
Author(s):
WU WenjunXIE LingLI TingtingDING RenzhongHU Yijie
(Department of Cardiovascular Surgery,Daping Hospital of Army Medical University,Chongqing 400042,China)
关键词:
经导管主动脉瓣置换术主动脉瓣狭窄脑卒中脑保护脑保护装置抗血栓治疗
Keywords:
Transcatheter aortic valve replacementAortic stenosisStrokeCerebral protectionCerebral protection deviceAntithrombotic therapy
DOI:
10.16806/j.cnki.issn.1004-3934.2024.04.002
摘要:
经导管主动脉瓣置换术(TAVR)目前已成为主动脉瓣狭窄患者主要治疗方式之一,其适应证逐渐由中高危患者向低龄、低危患者扩展。脑卒中是TAVR术后较常见的并发症之一,其增加患者死亡率、降低生活质量并增加医疗成本。因此,围手术期进行脑保护是至关重要的。现就TAVR围手术期脑卒中及脑保护做简要综述。
Abstract:
Transcatheter aortic valve replacement (TAVR) has now become one of the main treatments for patients with aortic stenosis (AS),and its indications have gradually expanded from intermediate- and high-risk patients to younger and low-risk patients. Stroke is one of the most common complications after TAVR,increasing patient mortality,reducing quality of life,and increasing healthcare costs. Therefore,perioperative cerebral protection is crucial. This article briefly reviews perioperative stroke and cerebral protection after TAVR

参考文献/References:

[1]van Mieghem NM,Deeb GM,S?ndergaard L,et al. Self-expanding transcatheter vs surgical aortic valve replacement in intermediate-risk patients:5-year outcomes of the SURTAVI randomized clinical trial[J]. JAMA Cardiol,2022,7(10):1000-1008.
[2]Reardon MJ,van Mieghem NM,Popma JJ,et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients[J]. N Engl J Med,2017,376(14):1321-1331.
[3]Thourani VH,Kodali S,Makkar RR,et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients :a propensity score analysis[J]. Lancet,2016,387(10034):2218-2225.
[4]Huded CP,Tuzcu EM,Krishnaswamy A,et al. Association between transcatheter aortic valve replacement and early postprocedural stroke[J]. JAMA,2019,321(23):2306-2315.
[5]Fanning JP,Walters DL,Platts DG,et al. Characterization of neurological injury in transcatheter aortic valve implantation:how clear is the picture?[J]. Circulation,2014,129(4):504-515.
[6]Winter MP,Bartko P,Hofer F,et al. Evolution of outcome and complications in TAVR:a meta-analysis of observational and randomized studies[J]. Sci Rep,2020,10(1):15568.
[7]Giustino G,Dangas GD. Stroke prevention in valvular heart disease:from the procedure to long-term management[J]. EuroIntervention,2015,11(suppl W):W26-W31.
[8]Kapadia SR,Kodali S,Makkar R,et al. Protection against cerebral embolism during transcatheter aortic valve replacement[J]. J Am Coll Cardiol,2017,69(4):367-377.
[9]Schmidt T,Schlüter M,Alessandrini H,et al. Histology of debris captured by a cerebral protection system during transcatheter valve-in-valve implantation[J]. Heart,2016,102(19):1573-1580.
[10]Vlastra W,Jimenez-Quevedo P,Tchétché D,et al. Predictors,incidence,and outcomes of patients undergoing transfemoral transcatheter aortic valve implantation complicated by stroke[J]. Circ Cardiovasc Interv,2019,12(3):e007546.
[11]Schaff HV. Transcatheter aortic-valve implantation—At what price?[J]. N Engl J Med,2011,364(23):2256-2258.
[12]Kleiman NS,Maini BJ,Reardon MJ,et al. Neurological events following transcatheter aortic valve replacement and their predictors:a report from the CoreValve trials[J]. Circ Cardiovasc Interv,2016,9(9):e003551.
[13]Mentias A,Saad M,Girotra S,et al. Impact of pre-existing and new-onset atrial fibrillation on outcomes after transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2019,12(21):2119-2129.
[14]Mack MJ,Leon MB,Thourani VH,et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients[J]. N Engl J Med,2019,380(18):1695-1705.
[15]Vora AN,Dai D,Matsuoka R,et al. Incidence,management,and associated clinical outcomes of new-onset atrial?fibrillation following transcatheter?aortic valve replacement:an analysis from the STS/ACC TVT registry[J]. JACC Cardiovasc Interv,2018,11(17):1746-1756.
[16]Auffret V,Regueiro A,Del Trigo M,et al. Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve?replacement[J]. J Am Coll Cardiol,2016,68(7):673-684.
[17]Bjursten H,Norrving B,Ragnarsson S. Late stroke after transcatheter aortic valve replacement:a nationwide study[J]. Sci Rep,2021,11(1):9593.
[18]Makkar RR,Yoon SH,Leon MB,et al. Association between transcatheter aortic valve replacement for bicuspid vs tricuspid aortic stenosis and mortality or stroke[J]. JAMA,2019,321(22):2193-2202.
[19]Rodés-Cabau J,Dumont E,Boone RH,et al. Cerebral embolism following transcatheter aortic valve implantation:comparison of transfemoral and transapical approaches[J]. J Am Coll Cardiol,2011,57(1):18-28.
[20]Eggebrecht H,Schmermund A,Voigtl?nder T,et al. Risk of stroke after transcatheter aortic valve implantation (TAVI):a meta-analysis of 10,037 published patients[J]. EuroIntervention,2012,8(1):129-138.
[21]Lu H,Monney P,Hullin R,et al. Transcarotid access versus transfemoral access for transcatheter aortic valve replacement:a systematic review and meta-analysis[J]. Front Cardiovasc Med,2021,8:687168.
[22]Suhai FI,Varga A,Szilveszter B,et al. Predictors and neurological consequences of periprocedural cerebrovascular events following transcatheter aortic valve implantation with self-expanding valves[J]. Front Cardiovasc Med,2022,9:951943.
[23]Butala NM,Makkar R,Secemsky EA,et al. Cerebral embolic protection and outcomes of transcatheter aortic valve replacement:results from the transcatheter valve therapy registry[J]. Circulation,2021,143(23):2229-2240.
[24]Voss S,Schechtl J,N?bauer C,et al. Patient eligibility for application of a two-filter cerebral embolic protection device during transcatheter aortic valve implantation:does one size fit all?[J]. Interact Cardiovasc Thorac Surg,2020,30(4):605-612.
[25]罗建方,李捷,孙英皓,等. 亚洲首次应用TriGUARD3在经导管主动脉瓣置换术中进行脑栓塞保护二例[J]. 中国循环杂志,2022,37(4):413-415.
[26]Nazif TM,Moses J,Sharma R,et al. Randomized evaluation of TriGuard 3 cerebral embolic protection after transcatheter aortic valve replacement:REFLECT Ⅱ[J]. JACC Cardiovasc Interv,2021,14(5):515-527.
[27]Samim M,Agostoni P,Hendrikse J,et al. Embrella embolic deflection device for cerebral protection during transcatheter aortic valve replacement[J]. J Thorac Cardiovasc Surg,2015,149(3):799-805.e1-2.
[28]Rodés-Cabau J,Kahlert P,Neumann FJ,et al. Feasibility and exploratory efficacy evaluation of the Embrella Embolic Deflector system for the prevention of cerebral emboli in patients undergoing transcatheter aortic valve replacement :the PROTAVI-C pilot study[J]. JACC Cardiovasc Interv,2014,7(10):1146-1155.
[29]Khan MZ,Zahid S,Khan MU,et al. Use and outcomes of cerebral embolic protection for transcatheter aortic valve replacement:a US nationwide study[J]. Catheter Cardiovasc Interv,2021,98(5):959-968.
[30]Radwan Y,Al-Abcha A,Salam MF,et al. Meta-analysis of the Safety and Efficacy of the Sentinel Cerebral Protection System in Transcatheter Aortic Valve Implantation[J]. Am J Cardiol,2021,152:169-170.
[31]Makkar RR,Fontana G,Jilaihawi H,et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves[J]. N Engl J Med,2015,373(21):2015-2024.
[32]李子昂,吴永健. 经导管主动脉瓣置换术后亚临床瓣叶血栓的研究进展[J]. 中国循环杂志,2022,37(4):436-439.
[33]Chakravarty T,S?ndergaard L,Friedman J,et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves:an observational study[J]. Lancet,2017,389(10087):2383-2392.
[34]Rashid HN,Gooley RP,Nerlekar N,et al. Bioprosthetic aortic valve leaflet thrombosis detected by multidetector computed tomography is associated with adverse cerebrovascular events:a meta-analysis of observational studies[J]. EuroIntervention,2018,13(15):e1748-e1755.
[35]D’Ascenzo F,Salizzoni S,Saglietto A,et al. Incidence,predictors and cerebrovascular consequences of leaflet thrombosis after transcatheter aortic valve implantation:a systematic review and meta-analysis[J]. Eur J Cardiothorac Surg,2019,56(3):488-494.
[36]Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J,2022,43(7):561-632.
[37]Ten Berg J,Sibbing D,Rocca B,et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation:a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI),in collaboration with the ESC Council on Valvular Heart Disease[J]. Eur Heart J,2021,42(23):2265-2269.
[38]Sherwood MW,Gupta A,Vemulapalli S,et al. Variation in antithrombotic therapy and clinical outcomes in patients with preexisting atrial fibrillation undergoing transcatheter aortic valve replacement:insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry[J]. Circ Cardiovasc Interv,2021,14(4):e009963.

相似文献/References:

[1]于海波,综述,梁延春,等.经导管主动脉瓣膜置换术后房室传导阻滞的预警[J].心血管病学进展,2016,(4):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
 YU Haibo,LIANG Yanchun.Predicting Factors of Atrioventricular Block after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2016,(4):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
[2]谢晓川,饶莉.经导管主动脉瓣植入术临床研究进展[J].心血管病学进展,2015,(6):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
 XIE Xiaochuan,RAO Li.Clinical Research Progress in Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2015,(4):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
[3]刘新民 宋光远 吴永健.左心室导丝起搏技术在经导管主动脉瓣置换术中的应用[J].心血管病学进展,2021,(4):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
 LIU Xinmin,SONG Guangyuan,WU Yongjian.Application of Left Ventricular Guidewire Pacing in Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2021,(4):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
[4]夏平.“8+2”心电图临床价值的研究进展夏平[J].心血管病学进展,2021,(9):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
 XIA Ping.Clinical Value of 8 Plus 2 ECG[J].Advances in Cardiovascular Diseases,2021,(4):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
[5]陈阳 赵庆豪 赵杰 吴永健.经导管主动脉瓣置换术时代慢性主动脉瓣反流诊治进展[J].心血管病学进展,2022,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
 CHEN Yang,ZHAO Qinghao,SONG Guangyuan,et al.Diagnosis and Treatment of Chronic Aortic Regurgitation in Transcatheter Aortic Valve Replacement Era[J].Advances in Cardiovascular Diseases,2022,(4):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
[6]董一娜 雷芳芳 宋启煦 王晶 杨艳.经导管主动脉瓣置换术后死亡风险预测模型系统评价[J].心血管病学进展,2022,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
 DONG Yina,LEI Fangfang,SONG Qixu,et al.Mortality Risk Prediction Models After Transcatheter?span>Aortic Valve Replacement:A Systematic Review[J].Advances in Cardiovascular Diseases,2022,(4):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
[7]张木馨 李丽英 阮海燕 何森.经导管主动脉瓣置换术后抗栓治疗进展[J].心血管病学进展,2022,(6):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]
 ZHANG Muxin,LI Liying,RUAN Haiyan,et al.Progress of Antithrombotic Therapy after?ranscatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(4):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]
[8]. 经导管主动脉瓣置换术术后抗栓治疗的研究进展 [J].心血管病学进展,2022,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
 DUAN ZhenyaWU Yongjian.Antithrombotic Therapy After Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2022,(4):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[9]胡正 陈祥 洲陈静.经导管主动脉瓣置换术后冠状动脉阻塞的研究进展[J].心血管病学进展,2023,(5):402.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.005]
 HUZheng,CHENXiangzhou,CHENJing.Coronary Occlusion of Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2023,(4):402.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.005]
[10]于子凯 许海燕 刘庆荣 吴永健.合并常见疾病对经导管主动脉瓣置换术患者预后的影响[J].心血管病学进展,2019,(5):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
 YU Zikai,XU Haiyan,LIU Qingrong,et al.Influence of ommon Accompanied Diseases on Prognosis of Patients after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2019,(4):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
[11]邵美华 周玉强 王萌萌 王宝珠 马翔.经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄研究进展[J].心血管病学进展,2020,(11):1184.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[12]李宗泽 何贵均 郑晓菲 蒋晖 刘汉雄.经导管主动脉瓣置换术后合并心房颤动的抗栓策略[J].心血管病学进展,2021,(10):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
 LI ZongzeHE GuijunZHENG XiaofeiJIANG HuiLIU Hanxiong.Optimal Antithrombotic Strategies after Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(4):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
[13]王卫卫 于子凯 吴永健 许海燕 刘庆荣.序贯综合心脏康复模式在经导管主动脉瓣置换术患者中应用现状[J].心血管病学进展,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
 WANG Weiwei,YU Zikai,WU YongjianXU HaiyanLIU Qingrong.The Status of Sequential Comprehensive Cardiac Rehabilitation in Patients?ndergoing Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(4):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
[14]张航 安景辉 石凤梧.极简式经导管主动脉瓣置换术的研究现状[J].心血管病学进展,2022,(9):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
 ZHANG Hang,AN Jinghui,SHI Fengwu.Minimalist Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(4):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
[15]达尼亚尔·迪力木拉提 施林 严飞.二叶式主动脉瓣发病机制及其临床诊治的研究进展[J].心血管病学进展,2023,(5):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]
 Daniyar·Dilmurat,SHI Lin,YAN Fei.The PathogenesisClinical Diagnosis and Treatment of Bicuspid Aortic Valve[J].Advances in Cardiovascular Diseases,2023,(4):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]

更新日期/Last Update: 2024-05-31